跳至主要内容
临床试验/NCT04149886
NCT04149886Unknown不适用

Cardiac Ganglionated Plexus Ablation Before Permanent Pacemaker Implantation in Patients With Sick Sinus Syndrome - A Multicenter, Randomized, Prospective Clinical Trial

China National Center for Cardiovascular Diseases2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2019年10月28日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
2
主要终点
Percentage of atrial pacing of permanent pacemaker programming

研究概览

简要总结

Different studies for cardiac ganglionated plexus(GP) ablation to treat vagal vascular syncope, sinus node dysfunction, and functional atrioventricular block have been published. Investigators have developed a more specific approach of cardiac, called cardioneuroablation . This treatment is based on a high-frequency stimulation (HFS) and/or anatomical landmarks to identify GPs in left atrium,which being targeted by radiofrequency catheter ablation. The feasibility of GPs ablation/cardioneuroablation has already been tested in our center in former studies in humans,with a favorable outcome for the patients involved. The results of the former studies have been submitted for publication. However, there are no prospective randomized studies to evaluate the efficacy and safety of atrial ganglionated plexus ablation for SSS before permanent pacemaker implantation.

The purpose of this study of GAPS in humans is to evaluate the efficacy and safety of cardioneuroablation in patients of sick sinus syndrome before they receive a permanent pacemaker.

详细描述

This is a multicenter,prospective, open, interventional study. All patients will undergo permanent pacemaker implantation. The study will involve eight different steps, from the screening procedure through study completion: screening, enrollment, pharmacological testing, randomization of group allocation, preprocedural assessment, procedure, follow-up, study completion. The dedicated study members (cardiac electrophysiologists, statisticians) and the PI are responsible for recording all data from the trial on the case report forms (CRFs) and completing the study database. The participants will be randomly allocated in a 1:1 ratio to either GPs ablation followed by permanent pacemaker implantation or pacemaker alone. Randomization will be conducted centrally by an independent statistics department(Oxford Medical Center of National Center for Cardiovascular Diseases, Beijing, China) and stratified by center and age(<50 or >=50 years); A dedicated independent physician will be responsible for the safety monitoring. The PI will permit inspection of the trial files and the database by national or international official controlling scientific authorities, if required. The PI will review and monitor completed CRFs and the database at regular intervals throughout the trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
14 Years 至 75 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Sign the informed consent form.
  • Diagnosed as SSS, with recurrent symptomatic bradycardia, blackouts, syncope, etc.
  • Meet the indications for permanent pacemaker implantation according to the 2018 Chinese pacemaker guidelines (Class I, Class IIa).
  • Positive reaction to atropine: The PP interval shortened by more than 20% or the sinus heart rate>60 bpm after intravenous injection of 2 mg of atropine.

排除标准

  • Age <14 years old or >75 years old.
  • Accompanied with complex congenital heart disease, valvular heart disease, cardiomyopathy and other chronic diseases, such as heart failure (NYHA grade III or IV).
  • Acute coronary syndrome or myocardial infarction occurred within 6 months. Cerebrovascular events (such as transient ischemic attack, stroke) or other cerebral blood supply disorders occurred within 3 months.
  • History of cardiac surgery and/or permanent cardiac pacemaker implantation.
  • TEE or CT found a left atrial thrombus and/or left atrial anteroposterior diameter > 55mm or LVEF < 35%.
  • Persistent atrial fibrillation, high-degree or complete atrioventricular block; double or triple fascicular block.

结局指标

主要结局

Percentage of atrial pacing of permanent pacemaker programming

时间窗: 12 months (±14 days)

Percentage of atrial pacing of permanent pacemaker at 12 months after the implantation of permanent pacemaker with program control.

Percentage of pacing of paced rhythm in Holter record

时间窗: 1 week

Percentage of pacing of paced rhythm in Holter record 1week after pacemaker implantation

次要结局

  • Percentage of sinus rhythm beats in Holter records(1 week, 3 months(±5 days), 6 months (±7 days),12 months (±14 days))
  • Freedom from syncope(1 week, 3 months(±5 days), 6 months (±7 days),12 months (±14 days))
  • Improvement of quality of life: Short Form-36 (SF-36) or Euroqol (EQ-5D)(1 week, 3 months(±5 days), 6 months (±7 days),12 months (±14 days))

研究者

发起方
China National Center for Cardiovascular Diseases
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Yan Yao, MD,PhD

Chief of First Department of Arrythmia Center

China National Center for Cardiovascular Diseases

研究点 (2)

Loading locations...

相似试验